JPWO2020132381A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132381A5 JPWO2020132381A5 JP2021535787A JP2021535787A JPWO2020132381A5 JP WO2020132381 A5 JPWO2020132381 A5 JP WO2020132381A5 JP 2021535787 A JP2021535787 A JP 2021535787A JP 2021535787 A JP2021535787 A JP 2021535787A JP WO2020132381 A5 JPWO2020132381 A5 JP WO2020132381A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- pxrd pattern
- room temperature
- coformer
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000001384 succinic acid Substances 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 2
- 238000005079 FT-Raman Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Claims (13)
a)単結晶構造の測定を室温で行った場合に、実質的に下記と同じ単位格子パラメーター
b)実質的に図1:
で示されるPXRDパターンが観測される;
c)4.5±0.2、9.5±0.2、14.6±0.2、16.3±0.2、17.6±0.2、21.4±0.2、22.4±0.2、および25.9±0.2から選択される2θの値を4つ以上含むPXRDパターン(室温で測定、CuKα λ=1.5418Å)である;
d)実質的に図5:
で示される赤外線スペクトルである;および/または
e)実質的に図6:
で示されるFT-ラマンスペクトルである。 3. The co-crystal of claim 2, wherein the co-crystal has one or more of the following characteristics:
a) When the single crystal structure measurements are performed at room temperature, the unit cell parameters are substantially the same as
b) Substantially Figure 1:
A PXRD pattern indicated by is observed;
c) a PXRD pattern (at room temperature) containing four or more 2-theta values selected from 4.5 ± 0.2, 9.5 ± 0.2, 14.6 ± 0.2, 16.3 ± 0.2, 17.6 ± 0.2, 21.4 ± 0.2, 22.4 ± 0.2, and 25.9 ± 0.2; , CuKα λ=1.5418 Å);
d) Substantially Figure 5:
is an infrared spectrum denoted by; and/or
e) Substantially Figure 6:
is an FT-Raman spectrum indicated by
a)実質的に下記と同じ単位格子パラメーター
b)実質的に図6:
で示されるPXRDパターンである;および/または
c)6.4±0.2、12.7±0.2、14.4±0.2、17.1±0.2、23.9±0.2、25.0±0.2、および26.6±0.2から選択される2θの値を4つ以上含むPXRDパターン(室温、CuKα λ=1.5418Å)である。 6. The co-crystal of claim 5, which is of the N-1 form and has one or more of the following characteristics:
a) Unit cell parameters substantially the same as
b) Substantially Figure 6:
is a PXRD pattern denoted by; and/or
c) a PXRD pattern containing 4 or more 2-theta values selected from 6.4 ± 0.2, 12.7 ± 0.2, 14.4 ± 0.2, 17.1 ± 0.2, 23.9 ± 0.2, 25.0 ± 0.2, and 26.6 ± 0.2 (room temperature, CuKα λ = 1.5418 Å).
a)単結晶構造の測定を室温で行った場合に、実質的に下記と同じ単位格子パラメーター
b)実質的に図12:
で示されるPXRDパターンである;および/または
c)4.6±0.2、5.5±0.2、8.4±0.2、11.3±0.2、14.6±0.2、16.4±0.2、21.1±0.2、24.2±0.2、および25.2±0.2から選択される2θの値を4つ以上含むPXRDパターン(室温、CuKα λ=1.5418Å)である。 6. The co-crystal of claim 5, which is of the N-2 form and has one or more of the following characteristics:
a) When the single crystal structure measurements are performed at room temperature, the unit cell parameters are substantially the same as
b) Substantially Figure 12:
is a PXRD pattern denoted by; and/or
c) 4 or more 2-theta values selected from 4.6 ± 0.2, 5.5 ± 0.2, 8.4 ± 0.2, 11.3 ± 0.2, 14.6 ± 0.2, 16.4 ± 0.2, 21.1 ± 0.2, 24.2 ± 0.2, and 25.2 ± 0.2 PXRD pattern (room temperature, CuKα λ=1.5418 Å).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783223P | 2018-12-21 | 2018-12-21 | |
US62/783,223 | 2018-12-21 | ||
PCT/US2019/067717 WO2020132381A1 (en) | 2018-12-21 | 2019-12-20 | Crystalline forms of a par4 inhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022514624A JP2022514624A (en) | 2022-02-14 |
JPWO2020132381A5 true JPWO2020132381A5 (en) | 2022-11-02 |
JP7473554B2 JP7473554B2 (en) | 2024-04-23 |
Family
ID=69187955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021535787A Active JP7473554B2 (en) | 2018-12-21 | 2019-12-20 | Crystals of PAR4 inhibitors |
Country Status (28)
Country | Link |
---|---|
US (1) | US20220064186A1 (en) |
EP (1) | EP3898638B1 (en) |
JP (1) | JP7473554B2 (en) |
KR (1) | KR20210109559A (en) |
CN (1) | CN113227102A (en) |
AU (1) | AU2019403348A1 (en) |
BR (1) | BR112021011688A2 (en) |
CA (1) | CA3124100A1 (en) |
CL (1) | CL2021001590A1 (en) |
CO (1) | CO2021008043A2 (en) |
DK (1) | DK3898638T3 (en) |
EA (1) | EA202191760A1 (en) |
ES (1) | ES2964404T3 (en) |
FI (1) | FI3898638T3 (en) |
HR (1) | HRP20231527T1 (en) |
HU (1) | HUE064830T2 (en) |
IL (1) | IL284222A (en) |
LT (1) | LT3898638T (en) |
MX (1) | MX2021007417A (en) |
PE (1) | PE20211963A1 (en) |
PL (1) | PL3898638T3 (en) |
PT (1) | PT3898638T (en) |
RS (1) | RS64900B1 (en) |
SA (1) | SA521422311B1 (en) |
SG (1) | SG11202106561RA (en) |
SI (1) | SI3898638T1 (en) |
WO (1) | WO2020132381A1 (en) |
ZA (1) | ZA202105115B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200127273A (en) * | 2012-04-26 | 2020-11-10 | 브리스톨-마이어스 스큅 컴퍼니 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
-
2019
- 2019-12-20 JP JP2021535787A patent/JP7473554B2/en active Active
- 2019-12-20 BR BR112021011688-5A patent/BR112021011688A2/en unknown
- 2019-12-20 ES ES19842497T patent/ES2964404T3/en active Active
- 2019-12-20 AU AU2019403348A patent/AU2019403348A1/en active Pending
- 2019-12-20 WO PCT/US2019/067717 patent/WO2020132381A1/en active Application Filing
- 2019-12-20 SI SI201930650T patent/SI3898638T1/en unknown
- 2019-12-20 LT LTEPPCT/US2019/067717T patent/LT3898638T/en unknown
- 2019-12-20 PE PE2021000917A patent/PE20211963A1/en unknown
- 2019-12-20 EP EP19842497.0A patent/EP3898638B1/en active Active
- 2019-12-20 CA CA3124100A patent/CA3124100A1/en active Pending
- 2019-12-20 FI FIEP19842497.0T patent/FI3898638T3/en active
- 2019-12-20 SG SG11202106561RA patent/SG11202106561RA/en unknown
- 2019-12-20 RS RS20231120A patent/RS64900B1/en unknown
- 2019-12-20 HU HUE19842497A patent/HUE064830T2/en unknown
- 2019-12-20 US US17/415,237 patent/US20220064186A1/en active Pending
- 2019-12-20 HR HRP20231527TT patent/HRP20231527T1/en unknown
- 2019-12-20 DK DK19842497.0T patent/DK3898638T3/en active
- 2019-12-20 MX MX2021007417A patent/MX2021007417A/en unknown
- 2019-12-20 PL PL19842497.0T patent/PL3898638T3/en unknown
- 2019-12-20 PT PT198424970T patent/PT3898638T/en unknown
- 2019-12-20 EA EA202191760A patent/EA202191760A1/en unknown
- 2019-12-20 CN CN201980085324.0A patent/CN113227102A/en active Pending
- 2019-12-20 KR KR1020217022513A patent/KR20210109559A/en active Search and Examination
-
2021
- 2021-06-17 SA SA521422311A patent/SA521422311B1/en unknown
- 2021-06-17 CL CL2021001590A patent/CL2021001590A1/en unknown
- 2021-06-18 CO CONC2021/0008043A patent/CO2021008043A2/en unknown
- 2021-06-20 IL IL284222A patent/IL284222A/en unknown
- 2021-07-20 ZA ZA2021/05115A patent/ZA202105115B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2425825C2 (en) | Amidoacetonitrile derivatives, pharmaceutical compositions containing said derivatives and use thereof in preparing medicinal agent | |
EP2635577B1 (en) | Substituted 6-fluoro-1h-pyrazolo[4,3-b]pyridines and use thereof | |
JP5373405B2 (en) | Selective androgen receptor modulator | |
EP2649045A2 (en) | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof | |
JP2005538124A5 (en) | ||
CN117045653A (en) | Diseases and treatments associated with toxic aldehydes | |
JP2006514991A5 (en) | ||
MA32088B1 (en) | Bicyclic derivatives of azabicyclic carboxamides, their preparation and their therapeutic application | |
JP2005508383A (en) | Crystalline polymorph of rimonabant, process for production and pharmaceutical composition containing the same | |
JP2024009114A (en) | As mineralcorticoid receptor antagonist compound crystalline form and preparation method thereof | |
JP2004523478A5 (en) | ||
CN101774958B (en) | I-type crystal of N-n-propyl-3-(4-methylphenyl)-4-(4-mesylphenyl)-2,5-dihydropyrrole-2-ketone and manufacturing method thereof | |
CA2523196A1 (en) | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | |
JPWO2020132381A5 (en) | ||
US10882817B2 (en) | Acetylsalicylic acid derivative crystal, its preparation method and use | |
DE60216948T2 (en) | 4'-METHANSULFONYLBIPHENYL DERIVATIVES AS HIGH-DETECTIVE CYCLOOXYGENASE-2 INHIBITORS | |
JPWO2020069024A5 (en) | ||
RU2020125154A (en) | CRYSTAL FORM OF OXOPICOLINAMIDE DERIVATIVE AND METHOD FOR ITS OBTAINING | |
JPS62108815A (en) | Dopamine-beta-hydroxylase inhibitor | |
CH647769A5 (en) | DISULFID COMPOUNDS. | |
RU2019106531A (en) | Quinazoline derivative salt crystal | |
RU2010136324A (en) | CYCLIC INDOL-3-CARBOXAMIDES, THEIR PRODUCTION AND USE OF THEM AS A MEDICINAL PRODUCT | |
TWI705065B (en) | Salt of morpholine derivative and its crystal form, manufacturing method thereof, pharmaceutical composition and use thereof | |
DE4220264A1 (en) | Phenyl-1,2,5-oxadiazole-carbonamide-2-oxide | |
HRP20231527T1 (en) | Crystalline forms of a par4 inhibitor |